Holen Sie sich die Stockscreener-App
2.90
3.57%
0.10
Schlusskurs vom Vortag:
$2.80
Offen:
$2.82
24-Stunden-Volumen:
54,622
Relative Volume:
0.26
Marktkapitalisierung:
$25.23M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.98M
KGV:
-0.2375
EPS:
-12.2116
Netto-Cashflow:
$-31.84M
1W Leistung:
+5.84%
1M Leistung:
-13.43%
6M Leistung:
-67.81%
1J Leistung:
-7.05%
1-Tages-Spanne:
$2.80
$2.95
1-Wochen-Bereich:
$2.63
$2.975
52-Wochen-Spanne:
$0.61
$14.68
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Firmenname
Briacell Therapeutics Corp
Sektor
Branche
Telefon
(604) 921-1810
Adresse
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Compare BCTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
2.90 | 25.23M | 0 | -30.98M | -31.84M | -12.21 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-02-14 | Eingeleitet | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Aktie (BCTX) Neueste Nachrichten
Briacell Therapeutics Corp (BCTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Briacell Therapeutics Corp (BCTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Briacell Therapeutics Corp (BCTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Briacell Therapeutics Corp (BCTX) Institutional Confidence - TradingKey
Briacell Therapeutics Corp (BCTXW) Institutional Confidence - TradingKey
Briacell Therapeutics Corp (BCTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Briacell Therapeutics Corp (BCTXW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Briacell Therapeutics Corp (BCTXW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Briacell Therapeutics Corp (BCTXW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Briacell Therapeutics Corp (BCTXW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Briacell Therapeutics Corp (BCTXW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Briacell Therapeutics Corp (BCTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Briacell Therapeutics Corp (BCTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Briacell Therapeutics Corp (BCTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Briacell Therapeutics Corp (BCTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Briacell Therapeutics Corp (BCTXW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Briacell Therapeutics Corp (BCTXW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Briacell Therapeutics Corp - TradingKey
Why Briacell Therapeutics Corp stock is rising today - Wealth Awesome
Why Briacell Therapeutics Corp stock is plummeting today - Wealth Awesome
BCTXZ SEC FilingsBriacell Therapeutics Corp 10-K, 10-Q, 8-K Forms - Stock Titan
BCTX Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift Shares Amid Revenue AbsenceROE Trend Analysis - newsline.com
BriaCell (NASDAQ: BCTX) ramps cancer trials but flags going concern risk - Stock Titan
BriaCell Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2026 - marketscreener.com
BriaCell receives FDA clearance for breast cancer therapy trial - Investing.com
BriaCell Therapeutics Completes Equity Offering to Fund Operations - The Globe and Mail
Immunotherapy Innovations: Increasing Survival in Metastatic Breast Cancer - Investing News Network
BriaCell (NASDAQ: BCTX) completes $4.71M best efforts common share sale - Stock Titan
BriaCell Therapeutics Prices $4.71 Million Share Offering at $3.25; ThinkEquity as Placement Agent - TradingView
Beyond the Lab: Top-Tier Clinical Validation in Biotech Investing - Investing News Network
BriaCell Therapeutics Rises After Hours as It Closes a $4.7-Million Share Offering - Moomoo
BriaCell Therapeutics Closes $4.7 Million Share Offering - marketscreener.com
BriaCell Therapeutics Announces Closing of Offering - Investing News Network
BriaCell Therapeutics (BCTX) raises ~$3.94M net in $3.25 share placement - Stock Titan
BriaCell Presents Positive Clinical Data at ASCO 2026 - Sahm
BriaCell Presenting Final Phase 2, Ongoing Phase 3 Data at ASCO Meeting - Moomoo
BriaCell Therapeutics Prices $4.7 Million Share Offering - Moomoo
BriaCell Down 9.3% as Prices Offering to Raise US$4.7 Million - marketscreener.com
What Does BriaCell's Latest Offering Mean for Shareholders - Kavout
BriaCell Therapeutics Announces Pricing of Offering - Moomoo
BriaCell Prices Public Offering With Shares at $X and Warrants at $Y - geneonline.com
What Does BriaCell's Latest Offering Mean for Investors - Kavout
BriaCell Offering Expected to Close June 2 >BCT.T - Moomoo
BriaCell prices $4.7M share offering to fund cancer immunotherapy development - Pluang
Briacell Therapeutics prices 1.45 million common shares at $3.25 per share - marketscreener.com
BriaCell Plans to Use Proceeds for Working Capital Requirements, General Corporate Purposes, Advancement of Business Objectives >BCT.T - Moomoo
Cancer immunotherapy firm BriaCell raises $4.7M for operations - Stock Titan
MSN Money - MSN
BCTXL Warrants Slip Slightly as Consolidation Continues Near $0.95TICK Divergence - newsline.com
(BCT) Risk-Controlled Trading Report (BCT:CA) - Stock Traders Daily
argenx to Host Myositis R&D Webinar on June 23, 2026 - Investing News Network
Finanzdaten der Briacell Therapeutics Corp-Aktie (BCTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):